45% of patients keep weight off a year after stopping GLP-1 drugs - real-world data challenges trial fears

Patients who stop taking semaglutide or tirzepatide do not, on average, regain significant weight in real-world clinical practice. That finding, from a Cleveland Clinic analysis of nearly 8,000 adults, diverges sharply from randomized clinical trials showing that patients who stopped these drugs regained more than half their lost weight within a year.

The difference, the researchers found, comes down to what happens next. In clinical trials, patients who stop the drug typically receive no alternative treatment. In real life, most people do not give up. They restart, switch medications, or pursue other weight management strategies.

The numbers after discontinuation

The study, published in Diabetes, Obesity and Metabolism, included 7,938 adults in Ohio and Florida who started injectable semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) for obesity or type 2 diabetes and then stopped within three to 12 months.

Among those treated for obesity, patients lost an average of 8.4% of body weight before discontinuation and regained just 0.5% one year later. Among those treated for type 2 diabetes, patients lost 4.4% before stopping and then lost an additional 1.3% over the following year.

In the obesity group, 55% did gain some weight in the year after stopping. But 45% either continued losing or maintained their weight. In the diabetes group, the split was even more favorable: 56% kept losing or stayed stable.

What patients did instead

The study tracked what treatments patients pursued after discontinuation:

• 27% switched to a different medication, including older obesity drugs or switching between semaglutide and tirzepatide
• 20% restarted their original medication
• 14% continued obesity treatment through lifestyle modification visits with dietitians or exercise specialists
• Less than 1% transitioned to metabolic or bariatric surgery

In total, roughly 61% of patients pursued some form of continued treatment. That ongoing engagement likely explains the modest average weight regain compared to the dramatic rebound observed in trials where treatment simply stopped.

Why people stop in the first place

The research group previously identified two primary reasons for discontinuation: cost or insurance coverage limitations and side effects, with cost being the dominant factor. Patients using the drugs for diabetes were more likely to restart, a difference the researchers attributed to more consistent insurance coverage for diabetes-related prescriptions compared to obesity indications.

This matters for interpreting the results. Patients who stopped due to cost may have been motivated and clinically responding well - they did not stop because the drug was not working. Their subsequent pursuit of alternatives is consistent with a population that wants to continue treatment but faces access barriers.

Trials versus reality

The gap between clinical trial results and real-world outcomes is not unusual in medicine, but it is particularly relevant here because the trial-based narrative - stop the drug, regain the weight - has shaped public discourse, insurance coverage decisions, and patient anxiety about GLP-1 medications.

Randomized trials are designed to isolate a single variable. They answer the question: what happens when you remove this specific drug and replace it with nothing? Real-world practice is messier and more adaptive. Patients and clinicians adjust. They try alternatives. They combine strategies. The average real-world outcome reflects not just the drug's pharmacology but the entire treatment ecosystem surrounding it.

The study's results do not mean that GLP-1 drug discontinuation is without consequences. More than half the obesity group did regain some weight. And the average masks individual variation - some patients likely regained substantially more than 0.5%. But the catastrophic rebound predicted by trial data appears to be substantially mitigated in practice.

What remains unknown

The study is retrospective and observational. It cannot determine whether the alternative treatments caused the weight maintenance or whether patients who pursued alternatives differed in motivation, health literacy, or socioeconomic resources from those who did not. Follow-up was limited to one year, and longer-term trajectories remain uncertain.

The research team plans to examine the comparative effectiveness of different alternative treatments - which switches, which lifestyle interventions, and which combinations produce the best outcomes after GLP-1 discontinuation. That analysis could provide clinicians and patients with more specific guidance for navigating what has become one of the most common questions in obesity medicine: what happens when I stop?